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It is well established that the normal human brain contains populations of neural stem/progenitor cells. Recent studies
suggest that they migrate toward a variety of CNS tissue injuries. In an investigation of the potential role of neural stem
cells in the pathogenesis of primary CNS lymphomas (NHL-CNS), we observed that neural stem/progenitor cells appeared
to accumulate at the border of the tumors with the brain and in the advancing edge of the tumors, in a pattern similar to
that seen with reactive gliosis. We identified neural stem/progenitor cells using standard immunohistochemical markers
thereof, including CD133, nestin, Group II Beta-tubulin, Musashi1, and the transcription factor Sox2, in neurosurgically
obtained specimens of NHL-CNS metastatic carcinoma , and metastatic melanoma . We had similar results with each of these
markers but found that Sox2 antibodies provided the clearest and most robust labeling of the cells at the borders of these
non-glial tumors. To exclude that the immunoreactive cells were actually neoplastic, double-label immunohistochemistry for
Sox2 and CD20 (for NHL-CNS), Sox2 and cytokeratin (CAM5.2, for carcinomas), or Sox2 and HMB45 (for melanomas) showed
that in each tumor type, Sox2-immunoreactive cells adjacent to and among the tumor cells were separate from
neoplastic cells. Sox2/GFAP double-labeling revealed a consistent pattern of Sox2 immunopositivity both in reactive
GFAP-immunopositive astrocytes and in GFAP-negative cells, at the interface of tumor and non-neoplastic brain.
These results suggest that neural stem/progenitor cells migrate to non-glial neoplasms in the CNS, are a source of
reactive astrocytes, and that Sox2 is a reliable immunohistochemical marker for these cells.
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The cancer stem cell hypothesis has revolutionized stud-
ies of cancer biology, including those of primary brain
tumors; it is now widely accepted that there is a stem
cell component in these as in most cancers. However
the related discovery of endogenous neural stem cells,
specifically mostly in the subventricular zone, has led to
the notion that neural stem cells might mediate re-
sponses to gliomas as well as representing a potentially
transformable pool of cells that may be the source of
such tumors. Endogenous neural stem/progenitor cells
distinct from tumor cells have an innate tropism for
both gliomas (Aboody et al. 2000) and non-glial CNS tu-
mors metastatic to the CNS (Aboody et al. 2006) and
also secrete antitumorigenic factors such as vanilloids
and BMP-7 (Chirasani et al. 2010; Stock et al 2012).* Correspondence: Millerdc@health.missouri.edu
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in any medium, provided the original work is pMacas et al. (2014) recently demonstrated that normal
neural progenitor cells, characterized by expression of
polysialated neural cell adhesion molecule (PSA-NCAM)
and BIII-tubulin populate the non-neoplastic but react-
ive brain tissue adjacent to both high-grade astrocyto-
mas and non-neural cerebral metastases. The migration
of neural stem cells into the region of a tumor in a
mouse model was shown to be mediated by vascular
endothelial growth factor (VEGF) secreted by tumor
cells signaling through VEGF Receptor 2.
Accurate characterization of the phenotype and func-
tion of endogenous neural stem/progenitor cells has
clinical applications given that intracerebral injection
of engineered neural stem/progenitor cells is being ex-
plored as treatment of neoplasms in the brain (Aboody
et al. 2006; Li et al. 2005; Rath et al. 2009; Sanson et al.
2002). Proposed tumoricidal mechanisms include gene
therapy using a viral-mediated HSV/tk/GCV process
(Li et al. 2005; Rath et al. 2009), or with cytosine deami-
nase for local generation of 5-fluorouracil at the site ofis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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trial for recurrent high-grade gliomas with the latter
strategy (ClinicalTrials.gov; Identifier: NCT01172964).
Neural stem cells and progenitor cells have been
shown to be selectively labeled by a variety of immuno-
histochemical markers, including the fetal brain inter-
mediate filament protein nestin (Sugawara et al. 2002),
the early neuronal differentiation marker group II beta-
tubulin (Sugita et al. 2005), the RNA-binding protein
Musashi1 (Okano et al. 2005), the transcription factor
Sox2 (Pevny and Nicolis 2010), and the stem cell antigen
CD133 (Li 2013). Sox2is an HMG box transcription fac-
tor with a documented role in embryogenesis and main-
tainance of pluripotent stem cells (Rath et al. 2009).
Sox2 has been implicated in the oncogenesis of glial
neoplasms in the brain (Alonso et al. 2011; Annovazzi
et al. 2011; Guo et al. 2011; Schmitz et al. 2007), and has
also been detected in cells of epithelial and mesenchymal
tumors (Basu-Roy et al. 2011; Girouard et al. 2012;
Mimeault and Batra 2011; Nakatsugawa et al. 2011), but
is also a marker of neural stem cells where its function
appears to be maintenance of pluripotency (Pevny and
Nicolis 2010). In addition to the endogenous role of
Sox2 in the non-pathologic state, populations of Sox2-
immunopositive cells have been detected near sites of
injury in the CNS in mice including lesions of demyelin-
ating disease, hypoglossal nerve avulsion, and penetrating
stab wounds (Fagerlund et al. 2011; Magnus et al. 2007;
Rasmussen et al. 2011). In human brain following sub-
arachnoid hemorrhage excised cortex had upregulated
mRNA expression of Sox2 and Musashi2 as evaluated by
PCR, in tandem with other markers of proliferation; this
was matched by immunohistochemical detection of
Musashi2 in tandem with the proliferation marker Ki67
(Sgubin et al. 2007) . In this study, we show that neural
stem/progenitor cells labeled by Sox2, Musashi1, nestin,
CD133 or beta-tubulin antibodies accumulate at the
borders of primary CNS B cell non-Hodkin lymphomas




All tissue samples were surgically removed, formalin-
fixed, and paraffin embedded between 2008 and 2012,
and were retrieved from the archives of the Department
of Pathology of the University of Missouri Hospitals and
Clinics with appropriate IRB approval with waiver of in-
formed consent. New sections cut from the paraffin
blocks at 5 μm thickness were used for immunohisto-
chemical stains (IHC).
The cases examined included 5 NHL-CNS, and 37
metastatic tumors in the brain (26 carcinomas, 11
melanomas).Immunohistochemistry
Antibodies:
IHC stains were done with antibodies to nestin (mouse
monoclonal, dilution 1:400; catalog no. MA1-46100,
Pierce, Rockford, IL), Musashi1 (rabbit polyclonal, dilu-
tion 1:100, catalog no. PA1-30152, Pierce), beta-tubulin
(rabbit polyclonal, dilution 1:100, catalog no. PA1-41331,
Pierce), CD133 (mouse monoclonal, dilution 1:2000,
catalog no. MA5-15875, Pierce), Sox2 (Goat polyclonal,
dilution 1:100; catalog No. AR2018, R&D Systems,
Minneapolis, MN), GFAP (Rabbit polyclonal, dilution
1:200; catalog No. 16825-1-AP, Proteintech Group,
Chicago, IL), CD20 (Rabbit polyclonal, dilution ready-
to-use; catalog No. PA1-37311, Pierce/Thermo-Fisher,
Rockford, IL), HMB45 (Mouse monoclonal, dilution
1:50; catalog No. M0634, DAKO, Carpinteria, CA), and
low molecular weight cytokeratins CAM5.2 (Mouse
monoclonal, dilution ready-to-use; catalog No. 349205,
Becton Dickinson, Franklin Lakes, NJ).
Initial IHC for nestin, Musashi1, beta-tubulin, CD133,
and Sox2 was performed on 5 NHL-CNS, and on 5 glio-
blastomas and 5 cases of systemic NHL (the latter two
as controls). Subsequently, based on the performance of
the various antibodies to stem/progenitor cell markers,
we concentrated on immunostains for Sox2 on 26 car-
cinomas metastatic to brain, and 11 melanomas meta-
static to brain. IHC was carried out with a standard
protocol involving heat-induced epitope retrieval with
Target Retrieval pH6 (S1700; DAKO, Carpinteria, CA).
Sox2 antibody incubation was performed for 1 hour at
room temperature and the antibody was detected using
a biotinylated link universal and streptavidin-HRP sys-
tem (K0690; DAKO). One case of carcinoma and three
of melanoma metastatic to brain were excluded from
further study due to paucity of non-neoplastic brain ad-
jacent to tumor in the tissue blocks selected for this
study.
Double-label IHC was performed with Sox2 and CD20
antibodies on five cases of CNS lymphoma; Sox2 and
HMB45 on 6 melanomas metastatic to brain; and Sox2
and CAM5.2 on 9 carcinomas metastatic to brain which
clearly lacked Sox2-immunopositive tumor cells. Add-
itionally, double-staining with Sox2 and GFAP was per-
formed on all cases of NHL-CNS and those metastatic
tumors for which the other double stains were done.
The procedure for staining with Sox2 was the same as
that described above except that the dual endogenous
enzyme block was performed before treating with the
primary Sox2 antibody. After treating with the DAB+
substrate chromagen system, the slides were rinsed with
distilled water. Three minutes of doublestain block was
followed by a 30-minute, 20-minute, or 10-minute incu-
bation with anti-CD20, CAM5.2/HMB45, and GFAP, re-
spectively. Visualization of the second antibody was
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manent Red System (K5361; DAKO) and the sections
were then counterstained with Mayer’s hematoxylin. Fol-
lowing counterstaining, slides were dried and cover-
slipped with Aqua-Mount (13800; Thermo Scientific).
Following the initial interpretation of the results, we
concluded that distinction between tumor cells and adja-
cent non-pathologic brain did not depend on immunohis-
tochemical labeling but was evident based on architecture
and cytology. Therefore we double-labeled 10 additional
cases of carcinoma metastatic to brain which had exten-
sive Sox2 immunopositivity in the tumor cells; these
cases were examined with Sox2/GFAP using the above
procedure.
Results
Initial immunostains for stem/progenitor cell markers in
sections of primary CNS lymphomas all showed variably
sparse immunoreactive cells at the interface between
groups of tumor cells and the adjacent (gliotic) brain
(Figure 1 all but Sox2; Figure 2 Sox2). Most of the cells
immunopositive for each of these markers were in the
peripheral portions of the tumor, and not deep in tumor
masses, or were in the gliotic brain bordering the tumor.A B C
D E F
G H I
Figure 1 Immunoreactivity for neural stem/progenitor cell markers in
different cases of NHL-CNS immunostained for Musashi-1. There are rare im
the adjacent gliotic brain. D-F) are sections of the same tumors immunostained
the brain of neural processes, but cytoplasmic immunopositivity is seen in only
within the tumors. G) Immunostain for nestin in a section from a case of NHL-C
the brain and the lymphoma, transgressing a short distance into the tumor bet
of NHL-CNS. In (H) there are immunopositive cells in the brain between two po
cell aggregates. For comparison to all of these, (J) is an immunostain for GFAP
between the tumor and the brain with a few entrapped GFAP-immunopositiv
All photomicrographs at original magnification of 400x.Some of the cells with immunoreactivity to Musashi1
(Figure 1A-C) were somewhat larger and resembled react-
ive astrocytes, as did some of the Sox2-immunopositive
cells (Figure 2); cells with immunoreactivity for nestin
(Figure 1G), CD133 (Figure 1H,I), and beta-tubulin(Fig-
ure 1D-F) were in general small. The pattern of distri-
bution of these cells was similar to, but less dense than,
that of reactive astrocytes in the same tumors as dem-
onstrated with GFAP immunostains (Figure 1J).
Sox2 IHC of 5 NHL-CNS with adjacent brain revealed
Sox2-immunopositive cells in every case, also primarily
at the interface of the tumor with the adjacent non-
neoplastic brain but also with occasional cells within the
masses of the tumors (Figures 2 and 3A). Similarly, Sox2
IHC of 25 metastatic carcinoma and 10 metastatic mela-
nomas in brain showed the same pattern, except that 16
and 2 cases of carcinoma and melanoma, respectively,
had abundant Sox2-immunopositive tumor cells, consistent
with previous literature (Basu-Roy et al. 2011; Girouard et al.
2012; Mimeault and Batra 2011; Nakatsugawa et al. 2011)
(not shown). In such cases, double-labeling with Sox2 and a
tumor marker would be superfluous and was not performed.
Both because we found Sox2 immunostains more





cases of primary CNS lymphoma (NHL-CNS). A-C) are sections of 3
munopositive cells within the tumor or at the edges of the tumor in
for group II beta-tubulin. There is some background immunopositivity in
in relatively rare cells along the edges of the tumors and, less frequently,
NS. There are some nestin-immunopositive cells along the border between
ween the lymphoma cells. H and I) Immunostains for CD133 in two cases
rtions of tumor; in (I) there are rare immunopositive cells within the tumor
in one of these cases, demonstrating maximal gliosis along the border
e astrocytes among the tumor cells deeper into the neoplastic aggregate.
A B
C
Figure 2 Immunostains of NHL-CNS with antibody to Sox2. Each photomicrograph A-C shows scattered sparse cells with Sox2-immunopositive
nuclei among the tumor cells. These were also present at the borders of the tumor with the adjacent brain, and were more numerous in the gliotic brain
than in the densely cellular portions of the tumors. Each photomicrograph at original magnification of 100x; insets showing immunopositive nuclei original
magnifications at 400x.
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example, are immunopositive in blood vessel cells as
well) or beta-tubulin, and because Sox2 is a nuclear anti-
gen suitable for double-label immunoperoxidase stains
with other cytoplasmic markers, we did further analyses
only with Sox2 as a marker of putative neural stem/pro-
genitor cells. Double-staining was performed with both
Sox2 and a second tumor-specific marker (CD20 for
NHL-CNS; CAM5.2 for carcinomas; HMB45 for melan-
oma) on the remaining 20 metastatic cases to determine
whether the Sox2-immunopositive cells might be part of
the neoplastic cell population (Figure 3). None of the 20
cases established not to have predominantly Sox2 immu-
nopositive tumor cells had any co-localization of Sox2 and
the tumor-specific marker, ie no lymphoma cells with
CD20 immunoreactivity were also Sox2-immunopositive,
no carcinoma cells with CAM5.2 immunopositive cyto-
plasm had any nuclear Sox2 immunoreactivity, and no
melanoma cells with HMB45 cytoplasmic immunopositiv-
ity had Sox2-immunoreactive nuclei (Figure 3). In these
sections of double-stained tumors and brain, the Sox2-
immunopositive cells were in the gliotic brain tissue adja-
cent to these non-neural neoplasms, with the greatest con-
centration close to the tumor edges and in the outer
portions of the tumors (particularly the lymphomas) with
fewer in brain at a distance from the tumors.
Clearly, the brain adjacent to these neoplastic pro-
cesses has reactive gliosis. This result raised the questionas to whether in these situations Sox2 represented a
marker of mature reactive astrocytes and not reactive
stem/progenitor cells. We investigated this question
using double-labeling of all of the tumor samples previ-
ously used for double-labeling with Sox2 and tumor-
specific antibodies with IHC for Sox2 and GFAP (Fig-
ure 4). These double-labeling experiments identified
three different immunophenotypic cell populations, all
in the gliotic brain adjacent to the neoplasms. These were:
(Aboody et al. 2000) astrocytes with Sox2-immunopositive
nuclei and GFAP-immunopositive cytoplasm; (Aboody
et al. 2006) astrocytes with GFAP-immunopositive cyto-
plasm without Sox2 immunoreactivity in their nuclei; and
(Alonso et al. 2011) Sox2-immunopositive nuclei with-
out any GFAP immunopositive cytoplasm (Figure 4).
These results suggest that these non-neural tumors
evoke a response by native neural stem/progenitor cells,
which migrate into the zone adjacent to the tumor and
among the tumor cells at the edges of the tumors, and
which then can mature into reactive astrocytes.
The consistent pattern of cells immunopositive for
neural stem cell or progenitor cell markers at the border
of tumor and normal brain and the distinction between
these cells and tumor cells achieved with double-labeling
for Sox2 and a tumor-specific marker prompted further
investigation into cases with Sox2-immunopositive tumor
cells. Thus, 10 cases of carcinoma metastasis with uni-
formly Sox2-immunopositive nuclei for which double-
AB C D
E F G
Figure 3 Double-label immunostains for Sox2 (brown, nuclear) and tumor-specific markers. A) NHL-CNS labeled for CD20 (red, cytoplasmic/
membranous) along with nuclear Sox2. The Sox2 immunoreactive nuclei are most numerous in the brain next to the tumor and at the interface with
the tumor. No cells are double-positive for CD20 and Sox2. Original magnification 200x. B) Another case of NHL-CNS double-labeled for CD20 and Sox2.
The scattered Sox2-immunopositive nuclei are each without associated cytoplasmic/membranous CD20 immunoreactivity. Original magnification 100x. C)
High magnification of Sox2-immunopositive nuclei within the NHL-CNS of (B). The absence of CD20-immunopositivity around the Sox2-immunopositive
(brown) nuclei is more obvious. Original magnification 400x. D) Another case of NHL-CNS with CD20-negative Sox2-immunopositive cells, and
CD20-immunopositive Sox2-negative tumor cells. Original magnification 400x. E) Metastatic carcinoma in brain, double-labeled for Sox2 (brown) and
for cytokeratin (CK) (antibody CAM5.2). The tumor cells have CK-immunoreactive cytoplasm with no nuclear Sox2 immunopositivity; the adjacent brain
has many cells with Sox2-immunopositive nuclei without cytoplasmic CK, with a few of these entrapped between tumor cells. Original magnification
200x. F) Another metastatic carcinoma in the brain, double-labled for Sox2 (brown) and for cytokeratin (antibody CAM5.2). As in “E”, the tumor cells
have CK-positive cytoplasm with no nuclear Sox2 immunoreactivity, while the adjacent brain has cells with Sox2-immunopositive nuclei without any
cytoplasmic CK immunoreactivity. Original magnification 200x. G) A metastatic melanoma immunostained for HMB45 (red) and for Sox2 (brown). The
Sox2-immunopositive nuclei are mostly within the adjacent brain at the edge of the tumor, and all lack HMB45 cytoplasmic immunoreactivity;
the melanoma cells are HMB-45 immunopositive but do not have any Sox2 nuclear immunoreactivity. Original magnification 400x.
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performed were used for Sox2/GFAP double-labeling.
The Sox2/GFAP double-labeling in these cases was con-
sistent with the previous cases, ie in the brain adjacent
to the tumor there were many cells with nuclear Sox2
immunopositivity which lacked cytoplasmic GFAP im-
munoreactivity, in addition to other cells which were
double-labeled and a third population of cells which
had only GFAP without nuclear Sox2 immunoreactivity.
One such case is illustrated in Figure 4n. Thus we ana-
lyzed 30 cases by double labeling for Sox2 and GFAP, all
of which showed the consistent pattern of Sox2-
immonopositivity described and illustrated here in Figures 2
and 3.
Discussion
Sox2 is an HMG box transcription factor, one of the
Yamanaka factors which exhibit characteristics of a mas-
ter regulator transcription factor. It has a documented
role in embryogenesis, including maintaining pluripo-
tency of embryonic stem cells (Rizzino 2009) and self-
renewal and multipotentiality of mesenchymal stem
cells. Loss of Sox2 expression has been shown to inhibitstem cell multipotentiality and induce cell differentiation
(Yi et al. 2012). Sox2 has also been shown to be effective
in stimulating de-differentiation of somatic cells into
pluripotent stem cells (Yoon et al. 2011). Interestingly, it
appears the functions of Sox2 in non-pathologic stem
cells of the body are likely exploited during oncogenesis.
Among cancers Sox2 has primarily been studied for a
role in oncogenesis of gliomas and it is expressed in
many gliomas, most notably glioblastomas (Annovazzi
et al. 2011; Guo et al. 2011; Schmitz et al. 2007). Levels
of Sox2 upregulation appear to correlate with aggres-
sive tumor behavior (Guo et al. 2011) and knockdown
of Sox2 in brain tumor stem cells results in a loss of
self-renewal, invasion, and migration of these cells
(Alonso et al. 2011). Immunopositivity for Sox2 has
been documented in examples of various other cancers
including, but not limited to, lung adenocarcinoma
(Nakatsugawa et al. 2011), melanoma (Girouard et al.
2012), breast carcinomas (Leis et al. 2012), and prostate
carcinoma (Mimeault and Batra 2011). Our study is
consistent with a wide variation of Sox2 expression;,
some metastatic tumors had widespread Sox2 nuclear
immunoreactivity; others, however, had none. Specifically,
A B
C D
Figure 4 Double-label immunostains for Sox2 (brown, nuclear) and GFAP (red, cytoplasmic) in non-neural CNS tumors. A) Metastatic
carcinoma in brain. There is reactive gliosis as indicated by the GFAP-positive cells (with red cytoplasm) at the edges of the neoplasm. Some of
these reactive astrocytes have Sox2-immunopositive (brown) nuclei; others do not. There are rare entrapped astrocytes and Sox2-positive nuclei
within the tumor. Original magnification 100x. B) Gliotic brain next to a metastatic carcinoma. The three populations of cells described in the text
are apparent here: cells with Sox2-immunopositive nuclei without GFAP-immunopositive cytoplasm; reactive astrocytes with GFAP-immunopositive
cytoplasm and Sox2-negative nuclei; and cells with double-labeling for both GFAP and Sox2. Rare cells with brown cytoplasm contain melanin and
are tumor cells. Original magnification 400x. C) Edge of a metastatic carcinoma in brain. Again there are variably Sox2 and GFAP immunopositive and
negative cells as described previously. Original magnification 400x. D) NHL-CNS with double labeling. There are fairly numerous Sox2-immunopositive
(brown) nuclei here near the edge of the tumor close to brain (not seen in this image), and a minority of those have associated GFAP-immunopositive
(red) cytoplasm. Some reactive astrocytes with GFAP immunoreactivity but no Sox2-immunopositivity are also entrapped among the neoplastic lymphoid
cells. Original magnification 400x.
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small cell and adenocarcinoma, clear cell renal cell carcin-
oma, squamous cell carcinoma, and poorly-differentiated
carcinomas of unproven origin.
With regard to the role of Sox2 in normal neural stem
cells, (Pevny and Nicolis 2010) outlined five major ob-
servations. 1) Sox2 is expressed in neural stem cells as
defined by the abilities of self-renewal and differentiation
into neurons, astroglia, and oligodendroglia. 2) Sox2
maintains properties of neural stem cells, including plur-
ipotency. 3) Maintenance of neural stem cells in the
brain and eye requires Sox2 expression. 4) Sox2 is essen-
tial for neural differentiation in the brain and eye. 5)
Sox2 function is both dose and context-dependent. This
study expands upon these functions of Sox2 in neural
stem cells to include a role in reactive neural stem/pro-
genitor cells accumulating at the interface of brain and
non-glial neoplasms of the CNS. Though the migrationof these cells has been widely reported, to our know-
ledge, the detection of Sox2-immunopositivity in this cell
population is a novel finding. This is also the first study
detecting such a neural stem/progenitor cell response to
neoplasms in the brain of specifically hematopoietic origin.
Our results suggest that these migrating stem/progenitor
cells mature into reactive astrocytes, transitioning through
a stage in which they maintain Sox2 nuclear immunoreac-
tivity while expressing cytoplasmic GFAP, and then go on
to lose the Sox2 expression as mature reactive astrocytes.
Though this is the first report of a Sox2 as a marker
of neural stem cell response to brain neoplasia, mice
models have previously detected Sox2-positive cells near
other sources of CNS injury including penetrating stab
wounds and hypoglossal nerve avulsion (Fagerlund et al.
2011; Magnus et al. 2007). In the former, most Sox2-
immunopositive cells failed to co-express GFAP, consist-
ent with our finding that only a minority of the reactive
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animal model of multiple sclerosis Rasmussen et al.
(Rasmussen et al. 2011) used BrdU/Sox2 double-
labeling to mark neural stem/progenitor cells, and found
BrdU/Sox2 positivity near areas of injury in chronic
demyelinating disease. They also noted that Sox2 expres-
sion was highest in the acute phase of demyelination with
a decrease in periventricular Sox2-immunopositive cells
in the chronic phase. This suggests that depletion of
neural stem cells may contribute to the progression of
demyelinating diseases.
Recently, (Macas et al. 2014) demonstrated similar
findings to ours: they showed that neural stem/progeni-
tor cells near brain tumors (gliomas and metastatic tu-
mors) were genetically distinct from the tumor cells. For
example, reactive stem/progenitor cells lacked Her2
amplification whereas adjacent breast carcinoma cells
had such amplification. While their methods were quite
different they reached the same conclusions we have,
that neural stem/progenitor cells migrate toward the
edges of tumors in reaction to them and are a separate
non-neoplastic population from the cells of the tumors.
Also, (Sgubin et al. 2007) showed up-regulation of
expression a variety of stem/progenitor cell markers,
including Sox2 and Musashi2, in brain tissue from 4
human patients with subarachnoid hemorrhages from
ruptured aneurysms, and, using immunostains, demon-
strated a correlation between Musashi2-immunopositive
cells and Ki67-immunopositive cells. Their findings also
suggest that neural stem cells and progenitor cells respond
to brain injuries by migration to as well as proliferation in
the site(s) of injury.
There is evidence that reactive glia possess the capabil-
ity for de-differentiation, however the degree to which
glia undergo this phenomenon under physiologic condi-
tions is incompletely understood (Costa et al. 2010;
Steindler and Laywell 2003; Yang et al. 2011). Therefore,
a possibility that emerges from these results is that the
population of cells expressing stem/progenitor cell markers
are reactive astrocytes undergoing de-differentiation and
thus have gained Sox2 nuclear immunoreactivity or CD133,
Musashi1, nestin, or beta-tubulin cytoplasmic immunoreac-
tivity, but are not derived from neural stem/progenitor
cells. In other words, the cell population might be locally
generated rather than represent a migration from a neural
stem cell niche. Though Sox2 is not a classic marker for
astrocytes, Sox2 immunopositivity in parenchymal astro-
cytes expressing GFAP has been documented (Komitova
and Eriksson 2004). Our results are at least now wholly
inconsistent with this possibility, however the paucity of
Sox2-immunopositive cells which co-express GFAP relative
to cells singularly expressing Sox2 is striking and favors the
hypothesis that these are cells migrating in from a stem/
progenitor cell niche and then differentiating to astrocytes,rather than the reverse. If Sox2-positive/GFAP-negative
cells originate from astrocytes, it would appear unlikely for
the majority of these cells to lack GFAP, an established
and reliable marker of astrocytes. Furthermore, the exten-
sive characterization of migrating neural progenitor cells
by (Macas et al. 2014) establishes a known population of
neural progenitor cells in the same “geographic” pattern as
that observed in this study. While it is theoretically possible
that the neural stem cell marker Sox2 could be expressed
in two separate cell populations (neural progenitor cells
and reactive astrocytes) which share the same anatomic
location with respect to brain neoplasms, it seems unlikely.
Conclusions
This study emphasizes the utility of Sox2 as a marker of
neural stem/progenitor cells, and supports the hypoth-
esis that these cells respond to non-glial neoplasms of
the CNS of epithelial and hematopoietic origin. At the
site of non-glial CNS neoplasms, these cells mature into
reactive astrocytes and thus serve as the origin of gliosis.
As the therapeutic use and understanding of neural stem/
progenitor cells increases in scope, detailed characterization
of the phenotype and physiology of neural stem/progenitor
cells will hopefully lead to novel treatments and an in-
creased survival, especially in cases of high-grade gliomas,
which have to this point, been refractory to treatment. Fur-
thermore, this study demonstrates that the detection of
neural stem/progenitor cells can be performed with a
marker, Sox2, readily available in many, if not most, surgical
pathology departments, using IHC, which has obviously be-
come an essential tool of all practicing surgical pathologists.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JGC carried out much of the immunohistochemical stains and helped draft and edit
the manuscript; DCM was the primary interpreter of all of the immunostains, helped
to devise the strategy for which stains to perform, and helped to draft and edit the
manuscript; DDC supervised the performance of all of the immunohistochemical
stains, devised novel variations of immunostain procedures, and helped to edit the
manuscript; QF helped with the immunostains and contributed to editing the
manuscript; NSL conceived the original project, collaborated with Dr Miller and Mr
Campbell in the design of the various immunostain experiments, helped to
interpret the data, and participated in editing the manuscript. All authors read and
approved the final manuscript.
Acknowledgments
Supported by a University of Missouri Office of Research Summer Fellowship
to JC.
Portions of this work were presented in poster form at the University of
Missouri Health Sciences Research Day, November 15, 2012, and at the
annual meeting of the American Association of Neuropathologists,
Charleston, South Carolina, June 22, 2013.
Author details
1Department of Surgery, Division of Neurological Surgery, The University of
Missouri School of Medicine, Columbia, Missouri, USA. 2Department of
Pathology & Anatomical Sciences, The University of Missouri School of
Medicine, M263 Medical Science Building, One Hospital Drive, Columbia, MO
65212, USA.
Campbell et al. SpringerPlus  (2015) 4:53 Page 8 of 8Received: 10 November 2014 Accepted: 8 January 2015References
Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herringer U,
Ourednik V, Black PM, Breakefield XO, Snyder EY (2000) Neural stem cells display
extensive tropism for pathology in adult brain: evidence from intracranial gliomas.
Proc Natl Acad Sci U S A 97:12846–12851
Aboody KS, Najbauer J, Schmidt NO, Yang W, Wu JK, Zhuge Y, Przylecki W, Carroll
R, Black PM, Perides G (2006) Targeting of melanoma brain metastases using
engineered neural stem/progenitor cells. Neuro-Oncology
8:119–126
Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza
L, Jauregi P, Lopez de Munain A, Sampron N, Aramburu A, Tejada-Solis S,
Vicente C, Odero MD, Bandres E, Garcia-Foncillas J, Idoate MA, Lang FF,
Fueyo J, Gomez-Manzano C (2011) Genetic and epigenetic modifications of
Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One
6:e26740
Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D (2011) SOX2 expression and
amplification in gliomas and glioma cell lines. Cancer Genomics-Proteomics
8:139–147
Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, Mansukhani
A, Basilico C (2011) Sox2 maintains self renewal of tumor-initiating cells in
osteosarcomas. Oncogene 31:2270–2282
Chirasani SR, Sternjak A, Wend P, Momma S, Campos B, Herrmann IM, Graf D,
Mitsiadis T, Herold-Mende C, Besser D, Synowitz M, Kettenmann H, Glass R
(2010) Bone morphogenetic protein-7 release from endogenous neural precursor
cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain
133:1961–1972
Costa MR, Götz M, Berninger B (2010) What determines neurogenic competence
in glia? Brain Res Rev 63:47–59
Fagerlund M, Jaff N, Danilov AI, Peredo I, Brundin L, Svensson M (2011)
Proliferation, migration and differentiation of ependymal region neural
progenitor cells in the brainstem after hypoglossal nerve avulsion.
Restor Neurol Neuros 29:47–59
Girouard SD, Laga AC, Mihm MC, Scolyer RA, Thompson JF, Zhan Q, Widlund HR,
Lee CW, Murphy GF (2012) SOX2 contributes to melanoma cell invasion.
Lab Invest 92:362–370
Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, Zhang Y, Ling EA, Gao J, Hao A
(2011) Expression profile of embryonic stem cell‐associated genes Oct4, Sox2
and Nanog in human gliomas. Histopathology 59:763–775
Komitova M, Eriksson PS (2004) Sox-2 is expressed by neural progenitors and
astroglia in the adult rat brain. Neurosci Lett 369:24–27
Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K,
Pandiella A, Rezola R, Martin AG (2012) Sox2 expression in breast tumours
and activation in breast cancer stem cells. Oncogene 31:1354–1365
Li S, Tokuyama T, Yamamoto J, Koide M, Yokota N, Namba H (2005) Bystander
effect-mediated gene therapy of gliomas using genetically engineered neural
stem cells. Cancer Gene Ther 12:600–607
Li Z (2013) CD133: a stem, cell biomarker and beyond. Exp Hematol Oncol 2:17
Macas J, Ku MC, Nern C, Xu Y, Buhler H, Remke M, Synowitz M, Franz K, Seifert V,
Plate KH, Kettenmann H, Glass R, Momma S (2014) Generation of neuronal
progenitor cells in response to tumors in the human brain. Stem Cells
32:244–257
Magnus T, Coksaygan T, Korn T, Xue H, Arumugam TV, Mughal MR, Eckley DM,
Tang SC, Detolla L, Rao MS, Cassiani-Ingoni R, Mattson MP (2007) Evidence
that nucleocytoplasmic Olig2 translocation mediates brain‐injury‐induced
differentiation of glial precursors to astrocytes. J Neurosci Res
85:2126–2137
Mimeault M, Batra SK (2011) Frequent gene products and molecular pathways
altered in prostate cancer–and metastasis-initiating cells and their progenies
and novel promising multitargeted therapies. Mol Med 17:949–964
Nakatsugawa M, Takahashi A, Hirohashi Y, Torigoe T, Inoda S, Murase M,
Asanuma H, Tamura Y, Morita R, Michifuri Y, Kondo T, Hasegawa T, Takahashi
H, Sato N (2011) SOX2 is overexpressed in stem-like cells of human lung
adenocarcinoma and augments the tumorigenicity. Lab Invest 91:1796–1804
Okano H, Kawahara H, Toriya M, Nakao K, Shibata S, Imai T (2005) Function of
RNA-binding protein Musashi-1 in stem cells. Exp Cell Res 306:349–356
Pevny LH, Nicolis SK (2010) Sox2 roles in neural stem cells. Int J Biochem Cell B
42:421–424Rasmussen S, Imitola J, Ayuso‐Sacido A, Wang Y, Starossom SC, Kivisäkk P, Zhu B,
Meyer M, Bronson RT, Garcia-Verdugo JM, Khoury SJ (2011) Reversible neural
stem cell niche dysfunction in a model of multiple sclerosis. Ann Neurol
69:878–891
Rath P, Shi H, Maruniak JA, Litofsky NS, Maria BL, Kirk MD (2009) Stem cells as
vectors to deliver HSV/tk gene therapy for malignant gliomas. Curr Stem Cell
Res Ther 4:44–49
Rizzino A (2009) Sox2 and Oct‐3/4: a versatile pair of master regulators that
orchestrate the self-renewal and pluripotency of embryonic stem cells. Wiley
Interdiscip Rev Syst Biol Med 1:228–236
Sanson M, Marcaud V, Robin E, Valéry C, Sturtz F, Zalc B (2002) Connexin 43–mediated
bystander effect in two rat glioma cell models. Cancer Gene Ther 9:149–155
Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, Wehner R,
Schackert G, Schackert HK, Fussel M, Bachmann M, Rieber EP, Weigle B (2007)
Identification of SOX2 as a novel glioma-associated antigen and potential target
for T cell-based immunotherapy. Brit J Cancer 96:1293–1301
Sgubin D, Aztiria E, Perin A, Longatti P, Leanza G (2007) Activation of endogenous
neural stem cells in the adult human brain following subarachnoid hemorrhage.
J Neurosci Res 85:1647–1655
Steindler DA, Laywell ED (2003) Astrocytes as stem cells: nomenclature,
phenotype, and translation. Glia 43:62–69
Stock K, Kumar J, Synowitz M, Petrosino S, Imperatore R, Smith ES, Wend P,
Purfurst B, Nuber UA, Gurok U, Matyash V, Walzlein JH, Chirasani SR, Dittmar
G, Cravatt BF, Momma S, Lewin GR, Ligresti A, De Petrocellis L, Cristino L, Di
Marzo V, Kettenmann H, Glass R (2012) Neural precursor cells induce cell
death of high-grade astrocytomas through stimulation of TRPV1. Nat Med
18:1232–1238
Sugawara K, Kurihara H, Negishi M, Saito N, Nakazato Y, Sasaki T, Takeuchi T (2002)
Nestin as a marker for proliferative endothelium in gliomas. Lab Invest
82:345–351
Sugita Y, Nakamura Y, Yamamoto M, Oda E, Tokunaga O, Shigemori M (2005)
Expression of tubulin beta II in neuroepithelial tumors: reflection of architectural
changes in the developing human brain. Acta Neuropathol 110:127–134
Yang H, Ling W, Vitale A, Olivera C, Min Y, You S (2011) ErbB2 activation
contributes to de-differentiation of astrocytes into radial glial cells following
induction of scratch-insulted astrocyte conditioned medium. Neurochem Int
59:1010–1018
Yi BR, Kim SU, Kim YB, Lee HJ, Cho MH, Choi KC (2012) Antitumor effects of
genetically engineered stem cells expressing yeast cytosine deaminase in
lung cancer brain metastases via their tumor-tropic properties. Oncol Rep
27:1823–1828
Yoon DS, Kim YH, Jung HS, Paik S, Lee JW (2011) Importance of Sox2 in
maintenance of cell proliferation and multipotency of mesenchymal stem
cells in low‐density culture. Cell Proliferat 44:428–440Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
